| Bortezomib+cyclophosphamide+dexamethasone (BCD, 7 courses) | VGPR |
| Bortezomib+dexamethasone+thalidomide (BDT, 3 courses) | CR |
| Bortezomib (maintenance) | — |
| Bortezomib+thalidomide (BT, maintenance) | CR |
| Thalidomide (maintenance) | CR |
| Bortezomib+(R, S)-lenalidomide+dexamethasone (BRD, 3 courses) | PD |
| Bortezomib+cyclophosphamide+dexamethasone+thalidomide (BCDT) | PR |
| Ixazomib+dexamethasone (ID) | PD |
| Ixazomib+pomalidomide+dexamethasone (IPD) | SD |
| Daratumumab+pomalidomide+dexamethasone (DPD, 9 courses) | PR |
Resection of thoracoscopic left lower lobe and chest wall mass (lung adenocarcinoma and multiple myeloma chest wall invasion) | PD |
| Daratumumab+carfilzomib+dexamethasone (DKD, 2 courses) | PD |
| Carfilzomib+cyclophosphamide+dexamethasone (KCD, 5 courses) | PR |
| Carfilzomib+bendamustine+dexamethasone (KBD, 2 courses) | PD |
| Daratumumab+carfilzomib+pomalidomide+dexamethasone (DKPD) | PR |